Showing results (1771-1780 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|January 1, 1982
Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycinG Hisano, I J Fidler
Cancer Immunology, Immunotherapy : CII|January 1, 1982
Reaction of the leukocytes of melanoma patients and control donors, including pregnant women, with melanoma- and fetus-derived materialsA J Cochran, G Todd, D M Hart, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1982
Chemiluminescence, suppression and cytotoxicity in peripheral blood mononuclear cells from solid tumor cancer patientsD P Braun, K P De Boer, J E Harris
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Initial immunochemical characterization of specific macrophage-arming factorR A De Weger, R J Vandebriel, H Slager, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Characterization of variant and parental-cross-protective immunity to immunogenic variants of a murine fibrosarcoma using the local adoptive transfer assayW Simcik, T L Sheu, S J LeGrue
Cancer Immunology, Immunotherapy : CII|May 19, 2015
Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trialYoshinari Maeda, Kiyoshi Yoshimura, Hiroto Matsui, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
A new high-yield continuous cell-culture system for lymphokine-activated killer cellsT Noto, Y Tokuda, Y Nakamura, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot studyV P Rutten, W R Klein, W A De Jong, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Human lymphokine-activated killer (LAK) cells. I. Depletion of monocytes from peripheral blood mononuclear cells by L-phenylalanine methyl ester: an optimization of LAK cell generation at high cell densityK H Leung
Cancer Immunology, Immunotherapy : CII|June 1, 2015
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefitEleftheria A Anastasopoulou, Ioannis F Voutsas, Theodora Keramitsoglou, et al.
Pageof 652